NKGen Biotech administers first dose of troculeucel for FTD under FDA-cleared compassionate use
NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in natural killer cell therapy, has taken a significant step in the treatment of frontotemporal ... Read More
Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU
In a landmark decision, the European Commission (EC) has authorized Biogen Inc.'s SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents ... Read More
Biohaven secures orphan drug status for verdiperstat in MSA treatment
Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for its investigational drug verdiperstat for treating multiple ... Read More